Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 325 participants.
Also called NCT01774968
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 325 participants
- Sponsor
- Registry
-
NCT01774968
-
- Other papers using this trial's data
- OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES β-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS
- Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial
- TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01774968. Randomized; no masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2015-05-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Human Regular U-500 Insulin
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01774968- Content hash
b99bf9b440b7d0770135148e7cf24063bf1df45f62f816e3fd94a5eb2e7854d0